Objects

Portable And Low-Cost Microscopic Imaging Device Makes a Small Case for Better Timing

A Toronto startup built a blood-test camera to escape Theranos's shadow, but its rivals already have FDA clearance for similar optics.

Clay-diorama editorial illustration related to Portable And Low-Cost Microscopic Imaging Device.

What changes in this design

Comparable technical language can sound similar while omitting the specific working relationship between named parts stated here.

The public description ties the terms together in one visible idea. Microscopic Imaging Device is the named microscopic imaging device in the source's described arrangement; Assembly is several parts joined so they can work as one unit.

That makes the patent easier to place beside similar work. A shared label is not enough; the comparable record needs the same stated working relationship between named parts.

The Webcam Vasu Nadella Added

In July 2023, Vasu Nadella closed a $48 million round for Vital Biosciences, his Toronto-area startup building a blood-testing machine called VitalOne, with money from Sam Altman, Marc Benioff and a handful of venture funds. He added something odd to the design: a webcam pointed at the sample chamber, so a patient can watch her own blood move through the machine while it runs. That is not a normal engineering choice. It is a rebuttal.

"We are trying to be totally different than anything you might imagine with Theranos," Nadella told a reporter at the time. He wasn't being coy. Theranos promised comprehensive lab results from a finger-prick's worth of blood, raised billions, and dissolved in 2018 after investigators found most of its tests were quietly run on other companies' machines. Nadella knows the shadow is long: he has said the Theranos story shrank the pool of investors willing to fund diagnostics at all.

The Eye Inside VitalOne

Filed as a U.S. provisional in March 2023, carried through an international application a year later, and published in the U.S. this September as US20260259399A1, the filing names Vital Biosciences as assignee and two inventors, Iman Khodadadzadeh and Eric Mahoney. It isn't the blood-testing machine itself. It's the eye inside it: a lens assembly built for a short working distance, paired with a light source that illuminates or excites the sample and a detector that reads what comes back, arranged in what optics engineers call an epiconfiguration - light in and light out through the same side of the sample, rather than all the way through it. That geometry is standard in fluorescence microscopy. Cramming it into something light and cheap enough to sit on a countertop, next to the pump and the disk that spins the sample around, is the actual engineering claim here, and it's the one part of this filing I find genuinely credible.

That path, from provisional to international filing to national phase to publication, took three years door to door - unremarkable as patent timelines go, but worth noting against how slowly the actual product has moved.

Two Rivals Already Cleared

Vital's optics have company, and the company got there first. Sight Diagnostics' OLO analyzer uses lens-based digital microscopy, developed originally to screen blood samples for malaria, to count red cells, white cells and platelets from two drops of finger-prick blood, and it holds FDA clearance. PixCell's HemoScreen, built around a different imaging method the company calls viscoelastic focusing, has been cleared for point-of-care hematology since 2018 and picked up clearance for direct capillary sampling, without a collection tube, in September 2023. Both machines solve a version of the same problem this patent's lens is built to solve, and both did it years ago with a regulator's signature attached.

The Trouble Is the Drop, Not the Lens

None of that makes the lens a bad idea. What should worry a careful reader sits upstream of the optics, in the blood itself. A hospital study published in the American Journal of Clinical Pathology found that fingerstick capillary sampling, the same kind VitalOne depends on, failed often enough in practice that technicians had to lance a second or third finger in 15 percent of cases, and 30 percent of an initial batch of samples came back with too little volume to test. The samples that did work read differently than blood drawn from a vein: a hemolysis index averaging 163 units higher, potassium biased up by 1.6 mEq/L, bicarbonate biased down by 5.5 mmol/L. The paper's conclusion is blunt - capillary sampling should be used 'only in the most extenuating circumstance,' a line I kept rereading against VitalOne's own marketing. That is close to the exact failure this patent's device would need to avoid: not bad electronics, but the physical limits of what a drop of finger blood can honestly tell you.

Where the risk actually sits

My own take: Vital Biosciences has built a plausible camera. Whether it has built a trustworthy blood test is a separate question, and it's the one that matters to a patient, not an investor. More than three years after the funding round that made headlines, the company's own product page still states that 'VitalBio's technology has not yet been evaluated by the FDA nor is the VitalOne listed or cleared,' and that the device is 'not available for purchase.' Nadella has framed the goal as disrupting an $85 billion diagnostics industry, his figure, and I could not independently confirm it. What I can confirm is that two competitors reached patients and regulators first, using imaging built on a similar premise, and that the science on capillary blood hasn't grown any friendlier since Theranos. A patent is a claim about optics. It says nothing about a needle stick, a rejected sample, or a lab value that comes back wrong by more than a point of potassium. That gap, between a working lens and a trustworthy result, is where this story actually sits.

Sources

Reporting for this piece drew on the published filing and the references below.

The record, briefly. US20260259399A1, “Portable And Low-Cost Microscopic Imaging Device” The printed abstract describes a microscopic imaging device having a lens assembly with short working distance, light weight and/or multiple optical elements, a first light source assembly that illuminates or excites a sample at the working distance, and one or more detection assemblies that detect light from the sample, with the lens assembly, first light source assembly and at least one detection assembly positioned to form an epiconfiguration.

More angles on this

Lens Device And Camera Device Including Same Questions the Default ArrangementAnother reading from the same G02B classification family, optical elements, systems or apparatus.
Inside fiber optic connector assemblyAnother reading from the same G02B classification family, optical elements, systems or apparatus.
CPC G02B: Optical elements, systems or apparatusThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
CPC G01N: Investigating or analysing materials by determining their chemical or physical propertiesThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
Inside multi-tiered semiconductor waveguideAnother reading from the neighbouring G02F classification family, optical devices or arrangements for the control of light by modification of the optical properties of the media of the.

Read around this one:Public patent record USPTO published figure